Department of Oncology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China.
Department of Medicine, Health School of Linyi, Linyi, Shandong 276000, P.R. China.
Mol Med Rep. 2018 May;17(5):6705-6710. doi: 10.3892/mmr.2018.8678. Epub 2018 Mar 5.
Non-small cell lung cancer (NSCLC) is a primary sub-type of lung cancer with a high incidence rate and poor prognosis. The primary therapeutic treatment for NSCLC is chemotherapy, which is considered to be ineffective and excessively toxic. Novel therapeutic methods, particularly molecular targeted therapy, have attracted considerable attention. MicroRNAs (miRs) are reported to be potential biomarkers and targeted agents with roles in various types of tumors. Herein, the present study presented the observation of aberrant low expression of miR‑29c and associated overexpression of vascular endothelial growth factor A (VEGFA) in NSCLC tumor tissues. The effects of miR‑29c upon NSCLC tumor progression, including cell proliferation and cellular apoptosis, were investigated. The possible regulatory mechanism of action of miR‑29c on its direct target VEGFA and the phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine‑protein kinase (Akt) signaling pathway was examined using multiple methods, including reverse transcription-quantitative polymerase chain reaction analysis, dual luciferase assay and western blot analysis. The results demonstrated that miR‑29c expression was downregulated in NSCLC tumor tissues compared with normal tissues. A marked negative correlation in the expression of miR‑29c and VEGFA was observed in clinical NSCLC tissues and cultured NSCLC cells. Overexpression of miR‑29c may inhibit cell proliferation and accelerate the cellular apoptosis rate of NSCLC tumor cells. Furthermore, the overexpression of miR‑29c was demonstrated to be able to downregulate the expression levels of VEGFA and PI3K/Akt signaling pathway‑associated proteins. The results of the present study suggested that miR‑29c might regulate NSCLC tumor progression by targeting VEGFA.
非小细胞肺癌(NSCLC)是一种原发性肺癌亚型,发病率高,预后差。NSCLC 的主要治疗方法是化疗,但化疗的效果不理想且毒性过大。新型治疗方法,特别是分子靶向治疗,引起了广泛关注。研究表明,microRNAs(miRs)是一种有潜力的生物标志物和靶向治疗药物,在各种类型的肿瘤中发挥作用。本研究观察到 NSCLC 肿瘤组织中 miR-29c 的表达异常下调,以及血管内皮生长因子 A(VEGFA)的过表达。研究了 miR-29c 对 NSCLC 肿瘤进展的影响,包括细胞增殖和细胞凋亡。通过多种方法,包括逆转录定量聚合酶链反应分析、双荧光素酶报告基因检测和 Western blot 分析,研究了 miR-29c 对其直接靶标 VEGFA 及磷脂酰肌醇 3-激酶(PI3K)/ Rac-α 丝氨酸/苏氨酸蛋白激酶(Akt)信号通路的可能调控机制。结果表明,与正常组织相比,miR-29c 在 NSCLC 肿瘤组织中的表达下调。在临床 NSCLC 组织和培养的 NSCLC 细胞中,miR-29c 的表达与 VEGFA 的表达呈显著负相关。过表达 miR-29c 可抑制 NSCLC 肿瘤细胞的增殖并加速其细胞凋亡率。此外,过表达 miR-29c 可下调 VEGFA 及 PI3K/Akt 信号通路相关蛋白的表达水平。本研究结果提示,miR-29c 可能通过靶向 VEGFA 调节 NSCLC 肿瘤的进展。